A 39-year-old male patient presented with"decreased bilateral visual acuity for more than one year". He has been infected with human immunodeficiency virus (HIV) for more than 10 years, and was diagnosed as "binocular panuveitis" "binocular optic disc vasculitis"in the local hospital, with no improvement after six months of systemic hormone shock, intermittent oral hormone and immunosuppressive treatment. Comprehensive examinations were conducted after arrival, Optical coherence tomography revealed the damage of posterior retina, macular edema, fluorescein fundus angiography showed diffuse punctate transmitted fluorescence and vascular leakage, rapid syphilis serotonin response (RPR) 1∶64, leading to the diagnosis of binocular syphilitic uveitis. After three weeks of antibiotic treatment, oral hormone sequential reduction treatment, disease control, vision recovery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.cn112142-20240909-00387 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fabrication of porous collagen-stem cells-dexamethasone scaffold as a novel approach for regeneration of mandibular bone defect.
Oral Maxillofac Surg
March 2025
Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Bone defects, particularly in the mandible, pose significant clinical challenges due to the limited regenerative capacity. Effective bone tissue engineering requires biomaterials that promote both osteogenesis and angiogenesis. This study developed an optimized collagen-nano hydroxyapatite scaffold loaded with dexamethasone and stem cells to enhance bone regeneration.
View Article and Find Full Text PDFCharacteristics and factors associated with treatment response among patients with eosinophilic fasciitis: a systematic review and meta-analysis.
Rheumatol Int
March 2025
Department of Internal Medicine, Division of Rheumatology, School of Medicine, University of Jordan, Amman, 11942, Jordan.
Background/objectives: Eosinophilic Fasciitis (EF) is a rare connective tissue disorder characterized by skin thickening. Few studies explored its characteristics and factors associated with treatment response.
Methods: PubMed, CENTRAL, Web of Sciences, and Scopus databases were searched in July 2023 to identify all published case reports of EF without restrictions on publication year or language.
Background: Neuroendocrine carcinomas (NECs) are rare tumors from hormone-secreting neuroendocrine cells, often within the gastrointestinal tract. The authors report what is, to their best knowledge, the first case of a small intestine NEC metastasizing to the temporomandibular joint (TMJ).
Case Description: A 60-year-old man came to the oral medicine, oncology, and orofacial pain clinic with a chief concern of left-sided jaw pain.
Advances in the treatment of polymyalgia rheumatica.
Rheumatology (Oxford)
March 2025
Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy.
Polymyalgia rheumatica (PMR) is a common inflammatory disorder affecting individuals over 50. The cornerstone of PMR treatment remains oral glucocorticoids (GCs), with initial doses tailored to the risk of relapse and comorbidities. However, relapses occur in up to 76% of cases, and long-term GC use is associated with significant toxicity, affecting up to 85% of patients.
View Article and Find Full Text PDFHighlights from the breakout session: optimising new treatments.
Rheumatology (Oxford)
March 2025
Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
This session presented emerging realworld evidence on novel glucocorticoid (GC) sparing therapies for ANCA-associated vasculitis (AAV). It covered the first-in-class oral C5a receptor antagonist avacopan for severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and antiinterleukin-5 therapies in the management of eosinophilic granulomatosis with polyangiitis (EGPA). Avacopan was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of AAV in 2021, following the phase 3 ADVOCAT E trial comparing oral avacopan to an oral GC taper for GPA and MPA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!